Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Ann Hematol · 2025 · PMC12334482 · PMID 40679584

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A more recent meta-analysis confirmed the lower number of TEs with ruxolitinib compared with BAT, although the overall difference did not reach statistical significance [ 82 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.